Apeiron RIA LLC Has $489,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Apeiron RIA LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 939 shares of the medical research company’s stock after acquiring an additional 171 shares during the quarter. Apeiron RIA LLC’s holdings in Thermo Fisher Scientific were worth $489,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Endeavor Private Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $30,000. D.B. Root & Company LLC boosted its stake in Thermo Fisher Scientific by 39.2% in the 4th quarter. D.B. Root & Company LLC now owns 920 shares of the medical research company’s stock worth $479,000 after purchasing an additional 259 shares during the period. Echo45 Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 6.1% in the 4th quarter. Echo45 Advisors LLC now owns 573 shares of the medical research company’s stock valued at $305,000 after purchasing an additional 33 shares during the period. True North Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. True North Advisors LLC now owns 624 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 55 shares in the last quarter. Finally, Traynor Capital Management Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $211,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TMO shares. Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. TD Cowen lifted their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $574.83 on Friday. The company has a market capitalization of $219.87 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a 50-day simple moving average of $531.52 and a 200 day simple moving average of $569.01.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the company posted $5.69 EPS. The firm’s quarterly revenue was up .2% on a year-over-year basis. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 44,850 shares of company stock valued at $24,666,097 in the last quarter. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.